AACR logo

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Abstract A266: Leucovorin rescue of high dose pralatrexate in mesothelioma xenografts.
Philip M. Tedeschi, Iqra Farooqi, Yamini Kathari, Joseph R. Bertino

Molecular Cancer Therapeutics Nov 2013, 12 (11 Supplement) A266; DOI: 10.1158/1535-7163.TARG-13-A266
Abstract A259: Characterization of next generation (Gen2.5) KRAS antisense inhibitors in NSCLC, PDAC, and CRC models.
Alexey S. Revenko, Gourab Bhattachrjee, Chris May, Brett P. Monia, A. Robert MacLeod

Molecular Cancer Therapeutics Nov 2013, 12 (11 Supplement) A259; DOI: 10.1158/1535-7163.TARG-13-A259
Abstract A256: Epigenetic priming with novel hypomethylating agent SGI-110 improved antitumor activity of CTLA-4 blockade in a syngenic mouse model.
Alessia Covre, Carolina Fazio, Hugues Nicolay, Giulia Parisi, Pietro Taverna, Mohammad Azab, Sandra Coral, Michele Maio

Molecular Cancer Therapeutics Nov 2013, 12 (11 Supplement) A256; DOI: 10.1158/1535-7163.TARG-13-A256
Abstract A257: Stereospecific trapping of PARP-DNA complexes by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-yin N. Huang, Amelie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow, Yves Pommier

Molecular Cancer Therapeutics Nov 2013, 12 (11 Supplement) A257; DOI: 10.1158/1535-7163.TARG-13-A257
Abstract A263: Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer.
Josephine Kam Tai Dermawan, Katerina Gurova, John Pink, Afshin Dowlati, Sarmishtha De, Goutham Narla, Neelesh Sharma, George Stark

Molecular Cancer Therapeutics Nov 2013, 12 (11 Supplement) A263; DOI: 10.1158/1535-7163.TARG-13-A263
Abstract A261: NPV-LDE-225 (Erismodegib) inhibits human prostate cancer stem cell growth in NOD/SCID IL2_γ^null mice by regulating Bmi-1 and microRNA-128.
Rajesh Nanta, Daniel Meeker, Mariana Rodova, Peter J. Van Veldhuizen, Sharmila Shankar, Rakesh K. Srivastava

Molecular Cancer Therapeutics Nov 2013, 12 (11 Supplement) A261; DOI: 10.1158/1535-7163.TARG-13-A261
Abstract A265: L-methionine restriction sensitizes triple-negative breast cancer cells to a TRAIL receptor-2 agonist by reducing the expression of the melanoma-associated antigen MAGE-D2.
Elena Strekalova, Dmitry Malin, David Good, Vincent Cryns

Molecular Cancer Therapeutics Nov 2013, 12 (11 Supplement) A265; DOI: 10.1158/1535-7163.TARG-13-A265
Abstract A260: BP-4-018, a novel inhibitor of STATs demonstrates anti-myeloma activity in preclinical models: Therapeutic implications of targeting aberrant STAT3 signaling in multiple myeloma.
Danielle C. Croucher, Zhi Hua Li, Brent DG Page, Ellen Wei, Patrick T. Gunning, Suzanne Trudel

Molecular Cancer Therapeutics Nov 2013, 12 (11 Supplement) A260; DOI: 10.1158/1535-7163.TARG-13-A260

Main menu

User menu

Search

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About MCT